Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Candel Therapeutics Inc (CADL)

135 + Investors. Track Smart Money conviction in CADL. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +31
Streak
2Q ▲
Buyers last Q
73%

Smart Money Signals — CADL

Based on 114 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added CADL than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
114 hedge funds hold CADL right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +37% more funds vs a year ago

fund count last 6Q
+31 new funds entered over the past year (+37% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 73% buying

80 buying30 selling
Last quarter: 80 funds were net buyers (39 opened a brand new position + 41 added to an existing one). Only 30 were sellers (22 trimmed + 8 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+25 vs last Q)

new funds entering per quarter
Funds opening a new CADL position: 16 → 14 → 14 → 39. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 40% entered in last year

■ 18% conviction (2yr+) ■ 42% medium ■ 40% new
Only 20 funds (18%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💎

Buying through price weakness — shares +83%, value +59%

Value
+58%
Shares
+83%
Last quarter: funds added +83% more shares while total portfolio value only changed +59%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

25 → 16 → 14 → 14 → 39 new funds/Q
New funds entering each quarter: 16 → 14 → 14 → 39. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
📊

Mixed cohorts — 23% veterans, 47% new entrants

■ 23% veterans ■ 30% 1-2yr ■ 47% new
Of 117 current holders: 27 (23%) held 2+ years, 35 held 1–2 years, 55 (47%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
🏆

Elite ownership — 43% AUM from top-100 funds

43% from top-100 AUM funds
35 of 113 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in CADL. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CADL

In 2026 Q1, 80 hedge funds were net buyers of CADL (39 opened a new position, 41 added to an existing one), while 30 reduced or exited (22 trimmed, 8 sold completely) — a 73% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. 43% of total institutional value in CADL is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +31 funds (more new holders than closures). Total institutional holders: 114.

Hedge Fund Ownership: CADL

How many hedge funds hold CADL — quarterly history vs. share price
Quarterly hedge fund ownership of CADL vs. share price

Market Analysis: CADL

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CADL

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Candel Therapeutics Inc (CADL) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CADL has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 53d ago
CADL
+19.9%
XLV
-16.8%

CADL outperformed XLV by +36.7% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 8d ago
CADL
+5.4%
XLV
+1.7%

Since the filing became public, CADL outperformed XLV by +3.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

11 top-rated funds 3 high-conviction
Consensus
4.7
/ 10
breadth
×
Elite
3.4
/ 10
conviction
Hedge Fund Positioning: CADL
135 + Investors

Track Smart Money conviction in CADL. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 135 114 18.42%
13F Shares 51M 44M 15.86%
Total Value $523M $215M 143.1%
New Positions 40 39 +1
Increased Positions 61 40 +21
Closed Positions 18 8 +10
Reduced Positions 24 21 +3
Total Calls 3 3 -
Total Puts 3 1 200.0%
PUT/CALL Ratio 1.0 0.33 Neutral

Statistics: CADL

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

135 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CADL. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CADL holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Acorn Capital Advisors, LLC 9.83% 3,497,948 $36.0M
2 Saturn V Capital Management LP 4.88% 3,303,686 $34.0M
3 Portolan Capital Management, LLC 1.35% 3,490,398 $36.0M
4 Halter Ferguson Financial Inc. 1.29% 772,461 $8.0M
5 Sands Capital Alternatives, LLC 0.68% 405,837 $4.2M
6 Rtw Investments, LP 0.56% 6,422,018 $66.1M
7 AlphaCentric Advisors LLC 0.32% 36,683 $378K
8 Torrey Growth & Income Advisors 0.25% 66,456 $740K
9 Birchview Capital, LP 0.23% 47,756 $492K
10 Tanager Wealth Management LLP 0.18% 198,175 $2.0M
11 Arete Wealth Advisors, LLC 0.10% 289,663 $3.0M
12 Virtus Investment Advisers, LLC 0.09% 38,224 $394K
13 Kennedy Capital Management LLC 0.09% 488,291 $5.0M
14 Boreal Capital Management LLC 0.06% 8,000 $82K
15 Kynam Capital Management, LP 0.06% 96,741 $996K
16 Axq Capital, LP 0.04% 31,460 $324K
17 Cookson Peirce & Co Inc 0.02% 60,000 $618K
18 Ghisallo Capital Management LLC 0.02% 100,000 $1.0M
19 Belpointe Asset Management LLC 0.02% 52,778 $544K
20 Y-Intercept (Hong Kong) Ltd 0.01% 68,472 $705K
21 WINTON GROUP Ltd 0.01% 37,300 $384K
22 Martingale Asset Management L P 0.01% 50,984 $525K
23 Cary Street Partners Financial LLC 0.01% 43,100 $444K
24 Stratos Wealth Advisors, LLC 0.01% 16,000 $165K
25 Profund Advisors LLC 0.01% 28,677 $295K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Candel Therapeutics Inc (CADL)

What does the Smart Money Trend signal show for CADL?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added CADL than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CADL?

More buyers than sellers — 73% buying: Last quarter: 80 funds were net buyers (39 opened a brand new position + 41 added to an existing one). Only 30 were sellers (22 trimmed + 8 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CADL holders?

Elite ownership — 43% AUM from top-100 funds: 35 of 113 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in CADL. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CADL?

Mostly new holders — 40% entered in last year: Only 20 funds (18%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Candel Therapeutics Inc (CADL) following the 2026 Q2 hedge fund 13F filings?

As of today, CADL has moved +5.4% since the 2026 Q2 13F filing date (August 14, 2026), compared to +1.7% for the XLV sector ETF — an outperformance of +3.7%. Since the quarter end (June 30, 2026), CADL has gained +19.9% vs -16.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →